Limitations of nonmyeloablative hematopoietic cell transplantation (HCT) for solid tumors.
Requirement for a HLA-compatible donor
Four-month or greater delay to onset of a GVT effect
Patients with rapidly progressive disease unlikely to benefit
Risk of regimen-related mortality
Complete responses rare
Sign In or Create an Account